Muriel Liberto

With Its Vanda Pharma And Berkheimer Memos, USPTO Provides Increased Clarity And Predictability In The Patent Eligibility Determination In A Further Boost For Stakeholders And Innovators In Personalized Medicine

FDA's New Biosimilar Action Plan Represents The Next Step for Improving Drug Competition

With Its Vanda Pharma And Berkheimer Memos USPTO Provides Increased Clarity, Predictability For Patent Eligibility In A Further Boost For Inventions In Personalized Medicine

Personalized Medicine Gets A Boost From Federal Circuit's Vanda Pharma Decision – PART II: Enforcement

Personalized Medicine Gets A Boost From Federal Circuit's Vanda Pharma Decision

USPTO Guidance For Examiners Takes Expansive View Of Myriad And Prometheus Decisions

FTCMay W aste Time Updating Price-Bias Guide, Attys Say

Leahy-Smith America Invents Act – What You Need to Know Now

Myriad Impact Of The Federal Circuit’s Decision In Myriad Genetics

Invention Assignment Following Stanford v. Roche: Implications For Technology Transfer And Government Contracts